An 8-Week Exploratory, Double-Blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-Induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged From at Least 18 Years to 80 Years.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Levetiracetam (Primary)
- Indications Drug-induced dyskinesia
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 16 Jul 2007 Status changed from in progress to completed.
- 17 Nov 2005 New trial record.